Development and Evaluation of a Fertility Preservation Patient Decision Aid for Women With Cancer.
22 avril 2016 mis à jour par: Georgina Jones, University of Sheffield
Development and Evaluation of a Patient Fertility Preservation Decision Aid for Women With Cancer: The Cancer, Fertility and Me Research Study
The aim of this research study is to develop a patient decision aid (PDA), and evaluate whether its integration within oncology services enable cancer services to effectively support and provide evidence based resources for women's fertility preservation decisions, following a diagnosis of any cancer type.
Aperçu de l'étude
Statut
Inconnue
Les conditions
Description détaillée
Women diagnosed with cancer have to make time-pressured decisions regarding fertility preservation with specialist fertility services whilst planning their cancer treatment with oncology services. Oncologists identify a need for resources enabling them to support women's fertility preservation decisions more effectively; and women report wanting more specialist information to make these choices across service pathways. This research will develop a new evidence-based patient decision aid (PDA) to address this unmet need and evaluate its acceptability to women and services when integrated into usual cancer care pathways at the point of cancer diagnosis and treatment planning.
The objectives are to:
- Develop a PDA for use by oncology teams to support women making fertility preservation choices, whilst having a recent cancer diagnosis.
- Assess the validity of the PDA to support women making informed decisions about fertility preservation before starting their cancer treatment.
- Evaluate the acceptability of the PDA to a) women making fertility preservation decisions whilst planning their cancer treatment and b) oncology and fertility health professionals supporting women's oncology and fertility treatment choices.
This research employs a series of prospective, observational surveys, employing both quantitative and qualitative methods to develop and evaluate the PDA.
Data will be collected during 5 time points:
- Face validity stage- The purpose of this stage is to assess the face validity of the PDA from women and health professionals. Qualitative and quantitative data collection will aim to explore understanding, the purpose of the PDA, and views on its utility.
- Evaluation Stage Baseline- Quantitative data collected from eligible women following their initial treatment planning consultation. Questionnaires are completed prior to reading the PDA.
- Evaluation Stage Time 1- Quantitative data collected from eligible women on arrival to their appointment at the Assisted Conception Unit (ACU). For those women who decide not to attend their appointment with the fertility expert the questionnaires will be either posted or handed to them at their next oncology appointment for completion, at the same time point.
- Evaluation Stage Time 2a- Quantitative data collected from eligible women following completion of their first round of chemotherapy.
- Evaluation Stage Time 2b- Qualitative interview data collected from eligible women following completion of their first round of chemotherapy, and from health professionals.
Type d'étude
Observationnel
Inscription (Anticipé)
98
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Royaume-Uni, S10 2JF
- Royal Hallamshire Hospital
-
Sheffield, South Yorkshire, Royaume-Uni, 10 2SF
- Jessop Fertility
-
Sheffield, South Yorkshire, Royaume-Uni, S10 2SJ
- Weston Park Hospital Cancer Charity
-
-
West Yorkshire
-
Leeds, West Yorkshire, Royaume-Uni, LS1 3EX
- Leeds General Infirmary
-
Leeds, West Yorkshire, Royaume-Uni, LS9 7TF
- St James University Hospital
-
Leeds, West Yorkshire, Royaume-Uni, LS14 6UH
- Leeds Centre for Reproductive Medicine
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
16 ans et plus (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Femelle
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
All women of a reproductive age (16yrs+), who have been diagnosed with cancer, and are undergoing or has undergone cancer treatment(s) which may impact fertility will be eligible.
The sample of women will be opportunistic and identified from those women referred to the study sites.
La description
Inclusion Criteria: All women aged >16 of a reproductive age, with a diagnosis of any cancer, undergoing cancer treatment(s) which may impact fertility
Exclusion Criteria: Women who have started menopause/ not of a reproductive age
-
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in decisional conflict (Decisional Conflict Scale)
Délai: Baseline (within 3 days after initial treatment planning consultation); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
This is a 16-item measure measuring the conflict inherent in the treatment decision encountered.
Scores > 37.5 on the overall scale (range 0-100) indicate high decisional conflict, which is characterised by decision delay and/or uncertainty about decision.
This will be administered to women.
|
Baseline (within 3 days after initial treatment planning consultation); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Preparation for Decision Making Scale
Délai: Face validity stage (within one day after reading the PDA)
|
This is a 10-item measure which assesses an individual's perception of how useful a DA is in preparing the respondent to communicate with their practitioner at a consultation focused on making a health decision.
High scores on the overall scale (range 0-100) indicate higher perceived levels of preparation for decision making.
It will be administered to women and health professionals.
|
Face validity stage (within one day after reading the PDA)
|
|
Change in perception (Preparation for Decision Making Scale)
Délai: Time 1- the next oncology or fertility consultation (within one month after reading PDA)
|
This is a 10-item measure which assesses an individual's perception of how useful a DA is in preparing the respondent to communicate with their practitioner at a consultation focused on making a health decision.
High scores on the overall scale (range 0-100) indicate higher perceived levels of preparation for decision making.
This will be administered to women.
|
Time 1- the next oncology or fertility consultation (within one month after reading PDA)
|
|
Change in decision making readiness (The Stage of Decision Making)
Délai: Baseline (within 3 days after initial treatment planning consultation); Time 1- the next oncology or fertility consultation (within one month after reading PDA); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
This is a 6 category tool to assess the individual's readiness to engage in decision making, progress in making a choice, and receptivity to considering or re-considering options.
Scores are rated 1-6 from not thinking about it at all, to considered options.
This will be administered to women.
|
Baseline (within 3 days after initial treatment planning consultation); Time 1- the next oncology or fertility consultation (within one month after reading PDA); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
|
The Decisional Regret Scale
Délai: Time 2b- after completion of first round of chemotherapy (within 3 months after reading the PDA)
|
This is a brief 5-item scale which measures "distress or remorse after a health care decision" using a 5-point Likert scale (1- strongly agree; 5- strongly disagree).
A score of 0 on the overall scale (range 0-100) indicates no regret; scores of 100 mean high regret.
This will be administered to women.
|
Time 2b- after completion of first round of chemotherapy (within 3 months after reading the PDA)
|
|
Change in health outcomes (The EQ-5D)
Délai: Baseline (within 3 days after initial treatment planning consultation); Time 2b- after completion of first round of chemotherapy (within 3 months after reading the PDA)
|
This is a standardised instrument for use as a measure of health outcome.
It consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, extreme problems.
This will be administered to women.
|
Baseline (within 3 days after initial treatment planning consultation); Time 2b- after completion of first round of chemotherapy (within 3 months after reading the PDA)
|
|
Change in anxiety (The State Trait Anxiety Inventory)
Délai: Baseline (within 3 days after initial treatment planning consultation); Time 1- the next oncology or fertility consultation (within one month after reading PDA); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
This is a brief 6-item version used to measure of state anxiety.
All items are rated on a 4-point scale (1-Almost never, 4-Almost always).
Higher scores indicate greater anxiety.
This will be administered to women.
|
Baseline (within 3 days after initial treatment planning consultation); Time 1- the next oncology or fertility consultation (within one month after reading PDA); Time 2a- after completion of first round of chemotherapy (within 3 months after reading PDA)
|
|
Count Data
Délai: Through study completion (an average of 18 months)
|
Count data will be collected of the number of DAs given to women and clinical staff, counts of use, and number of clicks on the 'Cancer, Fertility and Me' website will be recorded.
In addition we will record length of oncology and fertility consultations, and length of time to fertility and cancer treatment.
|
Through study completion (an average of 18 months)
|
|
Learner Verification Questionnaire
Délai: Face validity stage (within one day of reading the PDA)
|
This will consist of 4 items taken from the QQ-10, which is a measure of face validity which has been used in previous studies.
The 4 items will be measured on and a 5-point Likert scale (1- strongly agree; 5- strongly disagree).
The questionnaire will also comprise of 3 open end questions relating to the acceptability and utility of the PDA from womens and health professionals perspective.
This will be administered to women and health professionals.
|
Face validity stage (within one day of reading the PDA)
|
|
Qualitative Interviews (telephone)
Délai: Face validity stage (within 1 week after reading the PDA)
|
The telephone interview will take place with women and health professionals.
The interview schedule will focus Learner Verification (LV) (modified from an existing LV interview schedule) to seek further clarification on answers provided on the questionnaire, and to gain more in-depth information.
|
Face validity stage (within 1 week after reading the PDA)
|
|
Qualitative Interviews (face to face)
Délai: Time 2b- after completion of first round of chemotherapy (up to 3 months after reading the PDA)
|
The interview will take place with women.
The interview schedule for the face to face interviews will focus on Learner Verification (LV) (modified from an existing LV interview schedule) to explore the PDAs clarity and usefulness in planning care and making decisions between treatment options.
Additional areas the interview schedule will focus on include the PDAs likelihood of use, barriers to use in practice, whether or not the women and health professionals benefit from their delivery, usefulness of the PDA in aiding service transition, and how the women used the PDA.
|
Time 2b- after completion of first round of chemotherapy (up to 3 months after reading the PDA)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Georgina L Jones, D.Phil, Sheffield University
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 mai 2016
Achèvement primaire (Anticipé)
1 juin 2018
Achèvement de l'étude (Anticipé)
1 juin 2018
Dates d'inscription aux études
Première soumission
16 avril 2016
Première soumission répondant aux critères de contrôle qualité
22 avril 2016
Première publication (Estimation)
27 avril 2016
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
27 avril 2016
Dernière mise à jour soumise répondant aux critères de contrôle qualité
22 avril 2016
Dernière vérification
1 avril 2016
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 142491
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .